The data presented in this manuscript suggest that FDA-approved Syk inhibitor, fostamatinib, in combination with anti-PDL1 mAb and radiation, may be an effective strategy for NB and should be further explored in clinical investigations. The gene discussed is SYK; the disease is neuroblastoma.